Physician profile
Adam Mitchell
NPI 1881298727
$6,319.54
in general payments reported to CMS, 2019-2025
20 companies · $941 in 2025
The $941 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $1,802 · 2023: $1,780 · 2024: $1,355 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,075.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,276.54 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,048.80 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $945.32 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $855.31 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $351.76 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $328.28 | 2021-2024 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $302.00 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $272.98 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $235.60 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Indivior INC. | $201.75 | 2022-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $169.59 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $125.35 | 2023 | Qelbree |
| Axsome Therapeutics, INC. | $52.98 | 2023-2025 | Auvelity |
| Uswm, LLC | $39.46 | 2023 | Lucemyra, Zimhi |
| Exact Sciences Corporation | $34.24 | 2023-2024 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $18.81 | 2021 | |
| Optinose US, INC. | $17.10 | 2024 | |
| Cranial Technologies, INC | $15.16 | 2024 | Doc Band |
| Novo Nordisk INC | $14.51 | 2023 | Rybelsus |
| Noven Therapeutics, LLC | $14.00 | 2025 | Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.